Pulmonary Arteriovenous Fistulae Treatment & Management
- Author: Barry A Love, MD; Chief Editor: Howard S Weber, MD, FSCAI more...
The role of hormonal therapy in patients with recurrent bleeding secondary to GI or nasopharyngeal mucosa has been reported in the literature. Findings from these small studies have suggested a modest benefit. Anecdotal reports have also suggested successful treatment of epistaxis and GI hemorrhage by using danazol, octreotide, desmopressin, and aminocaproic acid. One preliminary study reported a decrease in the duration and number of episodes of epistaxis with bevacizumab.
Definite therapy for pulmonary arteriovenous malformations (PAVM) involves therapeutic embolization or surgical resection.
Catheter intervention - Therapeutic embolization
Embolization therapy (ie, embolotherapy) is a form of treatment based on occluding the feeding arteries to a pulmonary arteriovenous malformation.
The first successful case of embolotherapy of a pulmonary arteriovenous malformation was reported in 1977 and involved the use of handmade steel coils. Since then, embolization with coils and/or detachable balloons has been reported in numerous series of more than 250 patients. Other embolic materials include polyvinyl alcohol, cotton wool coils, and stainless steel coils.
Indications for embolotherapy include the following:
Progressive enlargement of the lesions
Feeding vessels of 3 mm or larger
The technique of coil embolotherapy involves the localization of the pulmonary arteriovenous malformation by means of angiography, followed by selective catheterization of the feeding artery. A steel coil is advanced through the catheter and placed distal to any branch of the vessel. Sometimes, more than 1 coil is required to completely occlude the vessel. Multiple pulmonary arteriovenous malformations can be embolized in a single session.
The second embolotherapeutic technique uses detachable balloons. After localization of a pulmonary arteriovenous malformation, a balloon catheter is exchanged over a guidewire and positioned at the neck of the pulmonary arteriovenous malformation.
Follow-up CT scans obtained 1 or more years after embolotherapy indicate that 96% of pulmonary arteriovenous malformations are either undetectable or reduced in size. These findings occur secondary to thrombosis and retraction of the aneurysmal sac after successful vascular obstruction.
In one series of 45 patients who underwent embolotherapy of large (>8 mm) pulmonary arteriovenous malformations, 98% of the pulmonary arteriovenous malformations were occluded during the initial attempt, 84% of patients remained successfully treated, and 16% of patients had persistent pulmonary arteriovenous malformations. The persistence of the pulmonary arteriovenous malformations was caused by recanalization of initial successful occlusion in 5 patients, and it was caused by interval growth of new feeding vessels in 3 patients. All 8 of the persistent pulmonary arteriovenous malformations were successfully occluded during a second procedure, although one pulmonary arteriovenous malformation required a third procedure for permanent occlusion.
A summary of 10 published series of therapeutic embolization for pulmonary arteriovenous malformation documented an average success rate of 98.7%. Balloon embolotherapy is generally used in pulmonary arteriovenous malformations with feeding vessels larger than 7-10 mm.
Embolotherapy appears to be the treatment of choice because major surgery, general anesthesia, and loss of pulmonary parenchyma may be avoided. Embolotherapy is a clear choice in patients with multiple or bilateral pulmonary arteriovenous malformations or in patients who are poor surgical candidates.
Postcatheterization precautions include hemorrhage, vascular disruption after balloon dilation, pain, nausea and vomiting, and arterial or venous obstruction from thrombosis or spasm.
Possible complications include rupture of blood vessels, tachyarrhythmias, bradyarrhythmias, and vascular occlusion.
Pleuritic chest pain is the most common complication and is observed in 12% of patients. This pain usually responds well to analgesics. Radiographic evidence of pulmonary infarction is observed in 3% of patients.
Air embolism during embolotherapy is suspected in 4.8% of patients; they developed transient symptoms such as angina, perioral paraesthesias, and bradycardia.
Device migration has been reported in 1.2% of embolization attempts.
Long-term follow-up evaluation has shown potentially serious complications in 2% of patients treated with embolotherapy.
Symptomatic recanalization was observed with 0.5% of procedures.
A new or increased pulmonary hypertension after embolization has been reported in several patients. Incidence of complication appears to be higher when the feeding vessels of more than 8 mm were occluded.
Until 1977, surgery was the only method of treatment. Ligation, local excision, segmentectomy, lobectomy, or pneumonectomy was performed in most cases. The reported perioperative mortality rate from surgery varied from 0-9%. Postoperative follow-up evaluation shows recurrence or enlargement of the pulmonary arteriovenous malformation in as many as 12% of patients. Surgery is the best choice for patients with an untreatable allergy to the contrast material.
Indications for surgery are progressive pulmonary arteriovenous malformation enlargement, paradoxic embolization, and symptomatic hypoxemia. The treatment of all pulmonary arteriovenous malformations with feeding vessels 3 mm or larger is also recommended.
Standard thoracic surgical techniques, such as ligation of pulmonary arteriovenous malformation, local excision, segmentectomy, lobectomy, or pneumonectomy, have been performed. In some cases, staged bilateral thoracotomies are performed. Recently, video-assisted thoracoscopic resection of a small pulmonary arteriovenous malformation has been performed.
Postoperative follow-up evaluation shows recurrence or enlargement of another pulmonary arteriovenous malformation in as many as12% of patients. During a follow-up evaluation performed 8 years after surgery, one case of stroke and one case of mortality related to pulmonary arteriovenous malformation occurred. Reports also suggest the development of pulmonary arterial hypertension. Moderate surgical techniques for the resection of pulmonary arteriovenous malformations are associated with a negligible mortality rate, but they are associated with the morbidities that accompany a thoracotomy.
According to various reported series, the perioperative mortality has varied from 0-9.1%. Most of the studies that reveal high mortality rates were reported before 1960. Postoperative morbidities have been well reported.
Patients with pulmonary arteriovenous malformations have reduced exercise tolerance.
Long-term clinical and imaging results of technically successful pulmonary arteriovenous malformations embolization in 150 patients were reviewed. Four hundred and fifteen pulmonary arteriovenous malformations were occluded during 205 procedures. Complications included respiratory symptoms (n = 13), cerebral ischemia (n = 4), brain abscess (n = 5), hemoptysis (n = 3), and seizure (n = 1). Imaging showed pulmonary arteriovenous malformation involution in 97% of embolized lesions and 11 residual lesions (2.8%) in 10 patients (6.9%). The other 97 previously small pulmonary arteriovenous malformations had enlarged to a significant size in 28 patients (18%). These data emphasize ongoing clinical and anatomic evaluation after pulmonary arteriovenous malformation embolization.
Large pulmonary arteriovenous fistulas (PAVFs) present significant difficulty for transcatheter treatment. However, initial experience with Amplatzer duct occluder (ADO) looks promising. One case series reported 5 patients, aged 3-73 years, with large PAVFs who underwent successful transcatheter closure with ADO. No complications occurred and the patients' arterial oxygen saturation and exercise tolerance improved. Thus, transcatheter closure of large PAVFs with the ADO is effective and can eliminate the need for surgical intervention. The newly designed Amplatzer vascular plug is undergoing clinical trials.
Ragsdale JA. Hereditary hemorrhagic telangiectasia: from epistaxis to life-threatening GI bleeding. Gastroenterol Nurs. 2007 Jul-Aug. 30(4):293-9; quiz 300-1. [Medline].
White RI Jr, Lynch-Nyhan A, Terry P, et al. Pulmonary arteriovenous malformations: techniques and long-term outcome of embolotherapy. Radiology. 1988 Dec. 169(3):663-9. [Medline].
Giordano P, Nigro A, Lenato GM, et al. Screening for children from families with Rendu-Osler-Weber disease: from geneticist to clinician. J Thromb Haemost. 2006 Jun. 4(6):1237-45. [Medline].
Pierucci P, Murphy J, Henderson KJ, Chyun DA, White RI Jr. New definition and natural history of patients with diffuse pulmonary arteriovenous malformations: twenty-seven-year experience. Chest. 2008 Mar. 133(3):653-61. [Medline].
Karam C, Sellier J, Mansencal N, et al. Reliability of Contrast Echocardiography to Rule Out Pulmonary Arteriovenous Malformations and Avoid CT Irradiation in Pediatric Patients with Hereditary Hemorrhagic Telangiectasia. Echocardiography. 2015 Jan. 32(1):42-8. [Medline].
Tomasian A, Lell M, Currier J, Rahman J, Krishnam MS. Coronary artery to pulmonary artery fistulae with multiple aneurysms: radiological features on dual-source 64-slice CT angiography. Br J Radiol. 2008 Sep. 81(969):e218-20. [Medline].
Poulikakos D, Theti D, Pau V, Banerjee D, Jones D. The impact of arteriovenous fistula creation in pulmonary hypertension: Measurement of pulmonary pressures by right heart catheterization in a patient with respiratory failure following arteriovenous fistula creation. Hemodial Int. 2012 Feb 23. [Medline].
Dupuis-Girod S, Ginon I, Saurin JC, Marion D, Guillot E, Decullier E, et al. Bevacizumab in patients with hereditary hemorrhagic telangiectasia and severe hepatic vascular malformations and high cardiac output. JAMA. 2012 Mar 7. 307(9):948-55. [Medline].
Grosso M, Groppo Marchisio F, Testa F, et al. Pulmonary arteriovenous malformations: percutaneous treatment preserving parenchyma in high-flow fistulae. Radiol Med. 2008 Apr. 113(3):395-413. [Medline].
Ishikawa Y, Yamanaka K, Nishii T, Fujii K, Rino Y, Maehara T. Video-assisted thoracoscopic surgery for pulmonary arteriovenous malformations: report of five cases. Gen Thorac Cardiovasc Surg. 2008 Apr. 56(4):187-90. [Medline].
Pollak JS, Saluja S, Thabet A, et al. Clinical and anatomic outcomes after embolotherapy of pulmonary arteriovenous malformations. J Vasc Interv Radiol. 2006 Jan. 17(1):35-44; quiz 45. [Medline].
Bialkowski J, Zabal C, Szkutnik M, et al. Percutaneous interventional closure of large pulmonary arteriovenous fistulas with the amplatzer duct occluder. Am J Cardiol. 2005 Jul 1. 96(1):127-9. [Medline].
McFaul RC, Tajik AJ, Mair DD, et al. Development of pulmonary arteriovenous shunt after superior vena cava- right pulmonary artery (Glenn) anastomosis. Report of four cases. Circulation. 1977 Jan. 55(1):212-6. [Medline].
Cloutier A, Ash JM, Smallhorn JF, et al. Abnormal distribution of pulmonary blood flow after the Glenn shunt or Fontan procedure: risk of development of arteriovenous fistulae. Circulation. 1985 Sep. 72(3):471-9. [Medline].
Laks H, Kaiser GC, Mudd JG, et al. Revascularization of the right coronary artery. Am J Cardiol. 1979 Jun. 43(6):1109-13. [Medline].
Gomes AS, Benson L, George B, Laks H. Management of pulmonary arteriovenous fistulas after superior vena cava- right pulmonary artery (Glenn) anastomosis. J Thorac Cardiovasc Surg. 1984 Apr. 87(4):636-9. [Medline].
Allen SW, Whitfield JM, Clarke DR, et al. Pulmonary arteriovenous malformation in the newborn: a familial case. Pediatr Cardiol. 1993 Jan. 14(1):58-61. [Medline].
Beck A, Dagan T, Matitiau A, Bruckheimer E. Transcatheter closure of pulmonary arteriovenous malformations with Amplatzer devices. Catheter Cardiovasc Interv. 2006 Apr 30. 67(6):932-937. [Medline].
Borsellino A, Giorlandino C, Malena S, et al. Early neurologic complications of pulmonary arteriovenous malformation in a newborn: an indication for surgical resection. J Pediatr Surg. 2006 Feb. 41(2):453-5. [Medline].
Chilvers ER, Whyte MK, Jackson JE, et al. Effect of percutaneous transcatheter embolization on pulmonary function, right-to-left shunt, and arterial oxygenation in patients with pulmonary arteriovenous malformations. Am Rev Respir Dis. 1990 Aug. 142(2):420-5. [Medline].
Dutton JA, Jackson JE, Hughes JM, et al. Pulmonary arteriovenous malformations: results of treatment with coil embolization in 53 patients. AJR Am J Roentgenol. 1995 Nov. 165(5):1119-25. [Medline].
Faughnan ME, Lui YW, Wirth JA, et al. Diffuse pulmonary arteriovenous malformations: characteristics and prognosis. Chest. 2000 Jan. 117(1):31-8. [Medline].
Faughnan ME, Thabet A, Mei-Zahav M, et al. Pulmonary arteriovenous malformations in children: outcomes of transcatheter embolotherapy. J Pediatr. 2004 Dec. 145(6):826-31. [Medline].
Ference BA, Shannon TM, White RI Jr, et al. Life-threatening pulmonary hemorrhage with pulmonary arteriovenous malformations and hereditary hemorrhagic telangiectasia. Chest. 1994 Nov. 106(5):1387-90. [Medline].
Gallitelli M, Guastamacchia E, Resta F, et al. Pulmonary Arteriovenous Malformations, Hereditary Hemorrhagic Telangiectasia, and Brain Abscess. Respiration. 2005 Jul 21. [Medline].
Gossage JR, Kanj G. Pulmonary arteriovenous malformations. A state of the art review. Am J Respir Crit Care Med. 1998 Aug. 158(2):643-61. [Medline].
Heutink P, Haitjema T, Breedveld GJ, et al. Linkage of hereditary haemorrhagic telangiectasia to chromosome 9q34 and evidence for locus heterogeneity. J Med Genet. 1994 Dec. 31(12):933-6. [Medline].
Johnson DW, Berg JN, Baldwin MA, et al. Mutations in the activin receptor-like kinase 1 gene in hereditary haemorrhagic telangiectasia type 2. Nat Genet. 1996 Jun. 13(2):189-95. [Medline].
Laks H, Williams W, Trusler G, Castaneda A. Subclavian arterioplasty for the ipsilateral subclavian-to-pulmonary artery shunt. Circulation. 1979 Aug. 60(2 Pt 2):115-9. [Medline].
Lenato GM, Guanti G. Hereditary Haemorrhagic Telangiectasia (HHT): genetic and molecular aspects. Curr Pharm Des. 2006. 12(10):1173-93. [Medline].
McAllister KA, Grogg KM, Johnson DW, et al. Endoglin, a TGF-beta binding protein of endothelial cells, is the gene for hereditary haemorrhagic telangiectasia type 1. Nat Genet. 1994 Dec. 8(4):345-51. [Medline].
Pooyan P, Shah L, Goli S, et al. Post-traumatic thoracic arteriovenous fistulas. Tenn Med. 2005 Apr. 98(4):181-3. [Medline].
Porteous ME, Burn J, Proctor SJ. Hereditary haemorrhagic telangiectasia: a clinical analysis. J Med Genet. 1992 Aug. 29(8):527-30. [Medline].
Puskas JD, Allen MS, Moncure AC, et al. Pulmonary arteriovenous malformations: therapeutic options. Ann Thorac Surg. 1993 Aug. 56(2):253-7; discussion 257-8. [Medline].
Remy J, Remy-Jardin M, Wattinne L, Deffontaines C. Pulmonary arteriovenous malformations: evaluation with CT of the chest before and after treatment. Radiology. 1992 Mar. 182(3):809-16. [Medline].
Shovlin CL, Guttmacher AE, Buscarini E, et al. Diagnostic criteria for hereditary hemorrhagic telangiectasia (Rendu- Osler-Weber syndrome). Am J Med Genet. 2000 Mar 6. 91(1):66-7. [Medline].
Sluiter-Eringa H, Orie NG, Sluiter HJ. Pulmonary arteriovenous fistula. Diagnosis and prognosis in noncomplainant patients. Am Rev Respir Dis. 1969 Aug. 100(2):177-88. [Medline].
Sperling DC, Cheitlin M, Sullivan RW, Smith A. Pulmonary arteriovenous fistulas with pulmonary hypertension. Chest. 1977 Jun. 71(6):753-7. [Medline].
Swanson KL, Prakash UB, Stanson AW. Pulmonary arteriovenous fistulas: Mayo Clinic experience, 1982-1997. Mayo Clin Proc. 1999 Jul. 74(7):671-80. [Medline].
Ueki J, Hughes JM, Peters AM, et al. Oxygen and 99mTc-MAA shunt estimations in patients with pulmonary arteriovenous malformations: effects of changes in posture and lung volume. Thorax. 1994 Apr. 49(4):327-31. [Medline].
Vase P, Holm M, Arendrup H. Pulmonary arteriovenous fistulas in hereditary hemorrhagic telangiectasia. Acta Med Scand. 1985. 218(1):105-9. [Medline].